Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J
Department of Breast Cancer, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Eur J Clin Invest. 2008 Jun;38(6):438-46. doi: 10.1111/j.1365-2362.2008.01956.x. Epub 2008 Apr 30.
Patients with triple-negative [oestrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER-2/neu) negative] breast cancer, accounting for about 15% of breast cancer cases, are associated with aggressive histology, poor prognosis and shorter survival. Osteopontin is a chemokine-like phosphorylated glycoprotein that plays important role in cancer progression and is found to be a metastasis-associated protein in breast cancer. The goal of the study was to evaluate osteopontin protein expression levels in triple-negative breast carcinomas to determine if they correlated with clinicopathological parameters, thus providing additional support for osteopontin functioning and better understanding of triple-negative breast cancer.
A database of 239 patients, in whom all three markers (ER, PR, and HER-2/neu) were available, was reviewed. We performed osteopontin protein expression analyses by means of immunohistochemistry on 117 breast carcinoma tissue samples, and then assessed the mean value of osteopontin expression against triple-negative status and clinicopathological parameters.
Of the 239 patients in the study, 47 were classified as triple negative. Of the 117 osteopontin-test patients in this cohort, mean osteopontin levels were significantly higher in the triple-negative breast cancers than in non-triple-negative subtype (P = 0.035). TNM (tumours, nodes, metastases) stage were significantly associated with osteopontin levels (P = 0.038). Univariate analysis showed tumour cell osteopontin positivity above an optimized cut-point to be significantly associated with decreased disease-free survival, but not overall survival. In the multivariate model, osteopontin was an independent prognostic factor for disease-free survival.
Patients with osteopontin overexpression develop predominantly triple-negative tumours. Osteopontin overexpression is associated with tumour aggressiveness and poor prognosis.
三阴性（雌激素受体（ER）阴性、孕激素受体（PR）阴性、人表皮生长因子受体2（HER-2/neu）阴性）乳腺癌患者约占乳腺癌病例的15%，其组织学表现侵袭性强、预后差、生存期短。骨桥蛋白是一种趋化因子样磷酸化糖蛋白，在癌症进展中起重要作用，并且被发现是乳腺癌中的一种转移相关蛋白。本研究的目的是评估三阴性乳腺癌中骨桥蛋白的蛋白表达水平，以确定其是否与临床病理参数相关，从而为骨桥蛋白的功能提供更多支持，并更好地了解三阴性乳腺癌。
回顾了一个包含239例患者的数据库，这些患者的所有三种标志物（ER、PR和HER-2/neu）数据均可用。我们通过免疫组织化学对117例乳腺癌组织样本进行骨桥蛋白蛋白表达分析，然后根据三阴性状态和临床病理参数评估骨桥蛋白表达的平均值。
在本研究的239例患者中，47例被分类为三阴性。在该队列中接受骨桥蛋白检测的117例患者中，三阴性乳腺癌的骨桥蛋白平均水平显著高于非三阴性亚型（P = 0.035）。TNM（肿瘤、淋巴结、转移）分期与骨桥蛋白水平显著相关（P = 0.038）。单因素分析显示，肿瘤细胞骨桥蛋白阳性高于优化切点与无病生存期降低显著相关，但与总生存期无关。在多变量模型中，骨桥蛋白是无病生存期的独立预后因素。
骨桥蛋白过表达的患者主要发生三阴性肿瘤。骨桥蛋白过表达与肿瘤侵袭性和预后不良相关。
Zotero 插件